Reuters logo
BRIEF-Genfit alerts public to potential risk of confusion between elafibranor and lanifibranor
September 20, 2017 / 4:31 PM / a month ago

BRIEF-Genfit alerts public to potential risk of confusion between elafibranor and lanifibranor

Sept 20 (Reuters) - Genfit SA:

* REG-GENFIT: RISK OF CONFUSION BETWEEN PPAR ALPHA/DELTA PHASE 3 DRUG CANDIDATE ELAFIBRANOR AND PPAR A/D/GAMMA PHASE 2 COMPOUND LANIFIBRANOR

* INITIAL ALERT ON POTENTIAL MEDICATION ERROR RAISED BY PRESCRIRE, AN INDEPENDENT CONTINUING EDUCATION ORGANIZATION FOR HEALTHCARE PROFESSIONALS

* RISK OF CONFUSION DUE TO BROAD SIMILARITY BETWEEN INNS ELAFIBRANOR AND LANIFIBRANOR, LATTER RE-USING 10 OF 11 LETTERS OF FORMER, INCLUDING WHOLE SUFFIX Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below